Gut bacterial extracellular vesicles in glucocorticoid-associated skeletal complications: evidence boundaries and translational challenges
- 1Department of Bone Diseases (Osteonecrosis), Luoyang Orthopedic Hospital of Henan Province (Orthopedic Hospital of Henan Province)
Abstract
Long-term or high-dose glucocorticoid (GC) therapy causes major skeletal complications, particularly glucocorticoid-induced osteoporosis (GIOP) and glucocorticoid-associated osteonecrosis of the femoral head (GIONFH). Bacterial extracellular vesicles (BEVs) produced by gut-resident bacteria are candidate inter-organ messengers, but the GC-specific evidence base is extremely limited. In an updated structured narrative search executed on 11–13 October 2026 and bounded to publications through 15 September 2026, one eligible in vivo dataset was identified that jointly incorporated GC exposure, administration of bacterially derived vesicles, and skeletal phenotyping: cultured Lactobacillus animalis -derived BEVs attenuated GC-induced osteonecrosis in mice. Within our operational intestinal-associated bacterial-source scope, 14 primary reports were retained: one directly evaluated GC-associated GIONFH and 13 addressed non-GC skeletal conditions. The core count is bounded by this source criterion and the documented search, rather than representing all bacterial OMV studies with skeletal outcomes. We classify the literature along two independent axes—vesicle source (bacterial versus host) and skeletal context (GC versus non-GC)—while keeping hypothesis-generating mechanisms, non-vesicular microbial products, non-skeletal vesicle evidence, and source-unresolved studies outside the matrix. We also distinguish community-derived gut microbiota-derived extracellular vesicles (GMEVs), cultured commensal-derived BEVs (cBEVs), and engineered BEVs, because these preparations are not biologically interchangeable. The anchor study is critically appraised, and GIOP is separated from GIONFH rather than treated as a single disease entity. Current direct bacterial-vesicle evidence supports proof of concept for GIONFH only; no eligible direct GC–bacterial-vesicle dataset for GIOP was identified within this search and source framework, and no eligible human study directly linking source-resolved circulating GMEVs to GC-associated skeletal outcomes was identified within this search framework. The principal translational barriers are source attribution; isolation and analytical standardization; biomarker analytical and clinical validation; biodistribution, PK–PD, and therapeutic delivery; safety, immunogenicity, and scalable manufacturing; and interspecies and human validation. Gut bacterial EVs should therefore be regarded as candidate mediators of a GC-associated gut–immune–bone–vascular axis rather than established drivers of skeletal injury. Immediate priorities are independent replication, testing of human-prevalent donor taxa, and prospective source-resolved clinical cohorts.
Related
- Targeting the secretory autophagy–extracellular vesicle interface: fate decisions and translational opportunities
- Soluble guanylate cyclase modulation in heart failure and chronic kidney disease: mechanisms, clinical evidence, and translational boundaries
- Formononetin as a Natural Product-Derived Candidate for Diabetic Microvascular Complications: Mechanistic Evidence, Pharmacokinetics, Formulation Strategies, and Translational Barriers
- Controlled postoperative red wine intake versus abstinence in habitual wine drinkers undergoing elective urological surgery (WISE): a translational randomized controlled trial assessing quality of life, surgical outcomes and complications.
- Persistent SIADH-like Hyponatremia Requiring Tolvaptan Despite Glucocorticoid Replacement in Rathke’s Cleft Cyst-Associated Hypophysitis: A Therapeutic Dilemma
BibTeX
@article{liu2026bacterial,
title = {{Gut bacterial extracellular vesicles in glucocorticoid-associated skeletal complications: evidence boundaries and translational challenges}},
author = {Zhe Liu and Xiuli Wu and Shengjie Zhang and Longfei Li and Lijing Zhao and Huimin Guo and Nan Sun and Jinju Li and Baoxia Sun and Xiaoxia Yan},
journal = {Frontiers in Endocrinology},
year = {2026},
month = nov,
doi = {10.3389/fendo.2026.2009751},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.2009751/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut bacterial extracellular vesicles in glucocorticoid-associated skeletal complications: evidence boundaries and translational challenges
AU - Zhe Liu
AU - Xiuli Wu
AU - Shengjie Zhang
AU - Longfei Li
AU - Lijing Zhao
AU - Huimin Guo
AU - Nan Sun
AU - Jinju Li
AU - Baoxia Sun
AU - Xiaoxia Yan
PY - 2026
DA - 2026/11/02
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.2009751
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.2009751/full
AB - Long-term or high-dose glucocorticoid (GC) therapy causes major skeletal complications, particularly glucocorticoid-induced osteoporosis (GIOP) and glucocorticoid-associated osteonecrosis of the femoral head (GIONFH). Bacterial extracellular vesicles (BEVs) produced by gut-resident bacteria are candidate inter-organ messengers, but the GC-specific evidence base is extremely limited. In an updated structured narrative search executed on 11–13 October 2026 and bounded to publications through 15 September 2026, one eligible in vivo dataset was identified that jointly incorporated GC exposure, administration of bacterially derived vesicles, and skeletal phenotyping: cultured Lactobacillus animalis -derived BEVs attenuated GC-induced osteonecrosis in mice. Within our operational intestinal-associated bacterial-source scope, 14 primary reports were retained: one directly evaluated GC-associated GIONFH and 13 addressed non-GC skeletal conditions. The core count is bounded by this source criterion and the documented search, rather than representing all bacterial OMV studies with skeletal outcomes. We classify the literature along two independent axes—vesicle source (bacterial versus host) and skeletal context (GC versus non-GC)—while keeping hypothesis-generating mechanisms, non-vesicular microbial products, non-skeletal vesicle evidence, and source-unresolved studies outside the matrix. We also distinguish community-derived gut microbiota-derived extracellular vesicles (GMEVs), cultured commensal-derived BEVs (cBEVs), and engineered BEVs, because these preparations are not biologically interchangeable. The anchor study is critically appraised, and GIOP is separated from GIONFH rather than treated as a single disease entity. Current direct bacterial-vesicle evidence supports proof of concept for GIONFH only; no eligible direct GC–bacterial-vesicle dataset for GIOP was identified within this search and source framework, and no eligible human study directly linking source-resolved circulating GMEVs to GC-associated skeletal outcomes was identified within this search framework. The principal translational barriers are source attribution; isolation and analytical standardization; biomarker analytical and clinical validation; biodistribution, PK–PD, and therapeutic delivery; safety, immunogenicity, and scalable manufacturing; and interspecies and human validation. Gut bacterial EVs should therefore be regarded as candidate mediators of a GC-associated gut–immune–bone–vascular axis rather than established drivers of skeletal injury. Immediate priorities are independent replication, testing of human-prevalent donor taxa, and prospective source-resolved clinical cohorts.
SN - 1664-2392
ER -